A new treatment for endometrial cancer has shown strong potential in a Phase 3 clinical trial. Drugmaker Merck announced that their investigational drug, sacituzumab tirumotecan (sac-TMT), achieved its primary goals of overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer.

The TroFuse-005 trial stands as a landmark study, being the first global Phase 3 trial to demonstrate significant improvement in survival compared to chemotherapy for these patients. According to the company’s press release, this is the first and only antibody-drug conjugate (ADC) to achieve such results in this clinical context.

An ADC targets cancer cells by delivering therapeutic agents, minimizing harm to healthy cells. Sac-TMT, the investigational drug, is administered biweekly via intravenous infusion.

The study involved 776 patients whose conditions had worsened after treatment with both platinum chemotherapy and immunotherapy. Participants were randomly assigned to receive sac-TMT or a physician-selected treatment option, which might include doxorubicin or paclitaxel chemotherapy. Patients were informed about their treatment.

Patients on sac-TMT exhibited clinically meaningful improvement compared to those on physician-selected treatments, as reported by the researchers.

The trial met response rate benchmarks, and side effects were similar to those in earlier studies of the drug. Although Merck did not provide specific statistics on survival benefits or side effects, the researchers plan to present the full Phase 3 data at a future medical meeting. The lead investigator, Dr. Domenica Lorusso, noted the drug’s potential to meet a critical unmet need for advanced endometrial cancer patients.

Despite recent advancements in immunotherapy, new options are urgently needed for patients with progressing disease. Dr. Brian Slomovitz, a trial investigator, emphasized the rising incidence and mortality of endometrial cancer, now the deadliest gynecologic malignancy in the United States.

Slomovitz highlighted the importance of survival improvements, noting that if upcoming data confirm these preliminary findings, sac-TMT could play a critical role in treatment. The magnitude of the survival benefit and toxicity profile will be vital in determining its impact.

Angelica Stabile, a lifestyle reporter for Fox News Digital, contributed to this report.